This inventor holds 2 USPTO granted patents. Top assignees: Shin-Etsu Chemical Co., Ltd., Shionogi Company Limited. Active years: 1983-1984.
Location History:
- Kusatsu, JP (1983)
- Osaka, JP (1984)
Company Filing History:
Years Active: 1983-1984
Title: Kiichiro Ohsuga: Innovator in Medicinal Formulations
Introduction
Kiichiro Ohsuga is a notable inventor from Kusatsu, Japan, recognized for his contributions to the field of medicinal formulations. He holds 2 patents that focus on innovative methods for drug delivery, particularly in rectal applications. His work has significantly advanced the pharmacokinetics of certain medications.
Latest Patents
Ohsuga's latest patents include a suppository containing a sulfamethoxazole/trimethoprim complex and a process for its preparation. This invention presents a one-to-one complex of sulfamethoxazole and trimethoprim, which is dispersed in a pharmaceutically acceptable carrier. It is designed to improve upon conventional preparations by enhancing the manufacturing process and pharmacokinetical properties. Another significant patent is for medicament capsules intended for rectal application. This invention minimizes the variation in absorbability of the effective ingredient among individuals, which is crucial for effective treatment. The capsules contain the active ingredient in liquid form, where the osmotic pressure plays a vital role in absorption.
Career Highlights
Throughout his career, Ohsuga has worked with prominent companies such as Shionogi Company Limited and Shin-Etsu Chemical Co., Ltd. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.
Collaborations
Ohsuga has collaborated with notable coworkers, including Yasushi Takagishi and Sadao Ohama. Their combined efforts have furthered advancements in medicinal formulations.
Conclusion
Kiichiro Ohsuga's innovative work in the field of medicinal formulations has made a significant impact on drug delivery methods. His patents reflect a commitment to improving patient outcomes through enhanced pharmacokinetics.

